口服重酒石酸长春瑞滨联合FT-207治疗晚期胃癌的临床疗效观察  

Oral vinorelbine bitartrate combined with FT-207 for treatment of advanced gastric cancer

作　　者：吴庭安[1] 

机构地区：[1]广东省江门市中心医院肿瘤科

出　　处：《白求恩军医学院学报》2010年第4期253-254,共2页Journal of Bethune Military Medical College

摘　　要：目的探讨口服重酒石酸长春瑞滨联合FT-207治疗胃癌的临床疗效。方法通过比较毒副作用和近期有效率，回顾性分析口服重酒石酸长春瑞滨联合FT-207治疗晚期胃癌的效果。结果单一药物治疗组（单一组）与联合药物治疗组（联合组）的毒副作用（恶心、呕吐、口腔炎和WBC减少等）发生率无显著性差异；联合组近期有效率高于单一组（P〈0．05）；两组间1、2年生存率无显著性差异。结论口服重酒石酸长春瑞滨联合FT-207治疗晚期胃癌，适用于失去手术机会或不愿接受手术治疗的患者。Objective To evaluate the clinical efficacy of taking vinorelbine bitartrate combined with FT-207 orally for advanced gastric tumor. Methods To review the efficacy of combined administration of the drugs for gastric carcinoma by comparing toxicity, side effect and the recent period efficacy of the combined drugs with those of only vinorelbine for treatment of 100 cases of advanced gastric cancer. Results There was no significant difference in toxicity and side effect such as nausea and vomiting between two methods. The recent period efficacy of the combined drugs was better than that of only vinorelbine. There was no difference in one-and 2-year survival rate between two methods. Conclusion Oral vinorelbine bitartrate combined with FT-207 is a suitable way for the cases having lost opportunities for operation and those not willing to have the surgical treatment.

关 键 词：长春瑞滨 FT-207 胃癌 

分 类 号：R735.2[医药卫生—肿瘤]